Moderna completes Cdn. manufacturing facility
February 26, 2024
By
Canadian Manufacturing
Moderna Canada completes construction of its mRNA vaccine manufacturing facility in Laval, Quebec. (CNW Group/Moderna, Inc.)
LAVAL — On Feb. 23, Moderna announced the completion of construction of its mRNA manufacturing facility in Laval, Quebec. The facility is expected to be ready to manufacture respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals and certifications, ensuring all vaccines manufactured meet the strictest quality, safety and performance standards.
The construction of this facility marks a milestone in Moderna’s strategic partnership with the federal government to support domestic preparedness for future pandemics for all Canadians. This initiative aims to generate and support high-skilled employment opportunities. The building of the facility was made possible in part by funding from the Government of Quebec through Investissement Québec.
This manufacturing site is reportedly designed to eliminate most fossil fuel usage, and benefits from Quebec’s electricity generated is from renewable resources.
Moderna currently has 45 therapeutic and vaccine programs in its pipeline across infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, including nine in late-stage development.
“With infectious diseases continuing to pose a significant health challenge, our mRNA platform can play a pivotal role against current and future threats. Canada’s role in global health is critical, and with this facility, Moderna is honoured to contribute to its robust scientific community and public health leadership in driving innovation and transformative medicine forward,” said Stéphane Bancel, Chief Executive Officer, Moderna.
“Completing the construction of our mRNA facility marks a groundbreaking moment for Moderna and Canada as we progress towards delivering a domestic mRNA vaccine supply chain. This building is a tangible example of concerted collaboration with the federal government, the government of Quebec, and the city of Laval, reflecting the lessons of the pandemic. We are proud to help drive Canada’s reputation as a mRNA centre of excellence and contributor to global health initiatives,” said Stefan Raos, General Manager, Moderna Canada.
